Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sindilizumab and Paclitaxel Polymeric Micelles in Advanced Non-squamous NSCLC
NCT05782426Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel and sindilizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Objective Response Rate at 2 years. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
paclitaxelsindilizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05782426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782426.